ARA-290 (cibinetide) regulatory status
Current status of ARA-290 (cibinetide) in the United States: Not eligible for compounding. In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of ARA-290 (cibinetide)?
Regulatory: Not eligible for compoundingWADA: WADA prohibitedVerified: Verified Sep 30, 2026
- FDA and compounding
- Investigational drug that has completed phase 2 trials but is not approved by FDA or any other regulator as of the last verification date. Because cibinetide is not a component of an approved drug, has no USP monograph, and is not on the 503A bulks list, a 503A pharmacy has no federal basis to compound it, and it is not eligible for 503B outsourcing. Products sold online as ARA-290 for human use are unapproved drugs.
- WADA
- WADA prohibited
- Access path
- No lawful United States access path identified on the last verified date outside a registered clinical trial.
- Not available as an FDA approved product and not eligible for compounding under section 503A or 503B.
- Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.
Full ARA-290 (cibinetide) page: evidence, dosing in the literature, and sources
How has the status of ARA-290 (cibinetide) changed over time?
No dated regulatory event has been recorded for ARA-290 (cibinetide). That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for ARA-290 (cibinetide) and the source of each dated event.
- [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [2]WADA Prohibited List, sections S0 non-approved substances and S2 peptide hormonesWADA, 2026
- [3]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026